Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
Go back to Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 33.68 -1.19 (3.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.87 | 52 Week High | $5.17 | |||
| Open | $34.63 | 52 Week Low | $0.94 | |||
| Day High | $34.81 | P/E | N/A | |||
| Day Low | $33.53 | EPS | $0.00 | |||
| Volume | 1,864,826 | |||||
